#1 Clinical Trials Search in Europe

Birtamimab

A groundbreaking clinical trial is underway to assess the effectiveness and safety of a new drug called Birtamimab in patients with advanced Light Chain (AL) Amyloidosis. This study focuses on individuals classified as Mayo Stage IV, the most severe stage of the disease. The trial aims to determine if Birtamimab, when combined with standard care, can improve survival rates and quality of life for these critically ill patients.

Table of Contents

Introduction

Birtamimab is an investigational drug being studied as a potential new treatment for patients with AL amyloidosis, a rare and serious disease.[1] This article will provide an overview of birtamimab and the ongoing clinical research to evaluate its effectiveness and safety.

What is Birtamimab?

Birtamimab is a medication that is administered intravenously (through an IV) at a dose of 24 mg/kg every 28 days.[1] It is being studied specifically for patients with Mayo Stage IV AL amyloidosis, which is an advanced stage of the disease.

How Birtamimab Works

While the exact mechanism of action is not detailed in the provided information, birtamimab is being investigated as a targeted therapy for AL amyloidosis. It is used in combination with standard chemotherapy treatments to potentially improve outcomes for patients with advanced disease.[1]

Clinical Trial Details

A large Phase 3 clinical trial is currently underway to evaluate birtamimab. Here are some key details about the study:

  • It is a randomized, double-blind, placebo-controlled trial
  • Approximately 220 newly diagnosed Mayo Stage IV AL amyloidosis patients will be enrolled
  • Participants will be randomly assigned to receive either birtamimab or a placebo in a 2:1 ratio
  • All patients will also receive standard chemotherapy treatment
  • The main goal is to assess if birtamimab can improve survival rates
  • The study includes a long-term open-label extension phase for eligible participants

This rigorous study design will help researchers determine if birtamimab is truly effective and safe for patients with advanced AL amyloidosis.[1]

Potential Benefits

The clinical trial aims to evaluate several potential benefits of birtamimab, including:

  • Improved overall survival: The primary goal is to see if birtamimab can help patients live longer.[1]
  • Enhanced physical function: Researchers will measure changes in the 6-Minute Walk Test to assess if birtamimab improves patients’ ability to perform physical activities.[1]
  • Better quality of life: The study will use a questionnaire called the Short Form-36 to evaluate if birtamimab improves patients’ overall health-related quality of life.[1]

Side Effects and Safety

As birtamimab is still being studied, comprehensive information about potential side effects is not yet available. The ongoing clinical trial will carefully monitor participants for any adverse reactions and assess the overall safety profile of the drug.[1]

Frequently Asked Questions

Who is eligible to receive birtamimab?

Currently, birtamimab is only available through clinical trials. The ongoing study is specifically for patients newly diagnosed with Mayo Stage IV AL amyloidosis.

How is birtamimab given?

Birtamimab is administered intravenously (through an IV) at a dose of 24 mg/kg every 28 days.

Will birtamimab replace current treatments for AL amyloidosis?

Birtamimab is being studied in combination with standard chemotherapy treatments. If proven effective, it may become an additional therapy option for patients with advanced AL amyloidosis, rather than replacing existing treatments entirely.

Summary

Aspect Details
Drug Name Birtamimab
Condition Treated AL Amyloidosis (Mayo Stage IV)
Administration Intravenous, 24 mg/kg every 28 days
Current Status In Phase 3 Clinical Trials
Primary Goal Improve overall survival
Additional Benefits Potential improvements in physical function and quality of life

Glossary

  • AL Amyloidosis – A rare disease where abnormal protein deposits build up in organs, affecting their function
  • Mayo Stage IV – An advanced stage of AL amyloidosis associated with poor prognosis
  • 6-Minute Walk Test – A test that measures the distance a patient can walk in 6 minutes to assess physical function
  • Intravenous (IV) – Administration of a substance directly into a vein
  • Phase 3 Clinical Trial – A large-scale study to confirm the effectiveness and safety of a new treatment

Trial sources

  • [1]: https://clinicaltrials.gov/study/NCT04973137
Aspect Details
Study Type Phase 3, randomized, double-blind, placebo-controlled
Participants Approximately 220 Mayo Stage IV AL Amyloidosis patients
Treatment Groups 2:1 ratio of Birtamimab to Placebo, both with standard care
Birtamimab Dosage 24 mg/kg intravenously every 28 days
Primary Outcome Time to all-cause mortality
Secondary Outcomes 6-Minute Walk Test, Quality of Life (SF-36)
Study Duration Double-blind phase + Optional 24-month open-label extension

FAQ

  • What is Birtamimab and how is it being studied? Birtamimab is a new drug being tested for Mayo Stage IV AL Amyloidosis patients. It's being studied in a Phase 3 clinical trial where it's given intravenously at a dose of 24 mg/kg every 28 days, alongside standard chemotherapy.
  • Who can participate in this clinical trial? The trial is enrolling approximately 220 newly diagnosed Mayo Stage IV patients with AL amyloidosis. These are patients with the most severe form of the disease.
  • How long does the trial last? The trial has two phases: a Double-blind Phase that lasts until a pre-defined number of events (deaths) occur, and an optional Open-label Extension Phase that can last up to 24 months or until the drug becomes commercially available.
  • What is the main goal of this clinical trial? The primary goal is to evaluate if Birtamimab can extend the survival time of patients with Mayo Stage IV AL Amyloidosis when added to standard care treatment.
  • What other outcomes are being measured in this trial? Besides survival time, the trial is also measuring changes in physical function through a 6-Minute Walk Test and assessing quality of life using the Short Form-36 questionnaire.

Ongoing Clinical Trials on Birtamimab

  • Study on Birtamimab and Bortezomib for Patients with Advanced Light Chain Amyloidosis

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +8

Glossary

  • AL Amyloidosis: A rare disease where abnormal proteins build up in organs, affecting their function. 'AL' stands for 'Amyloid Light chain'.
  • Mayo Stage IV: The most severe stage of AL Amyloidosis, indicating advanced disease with poor prognosis.
  • Birtamimab: An experimental drug being tested for the treatment of Mayo Stage IV AL Amyloidosis.
  • Standard of Care: The best known treatment currently available for a disease, in this case, a bortezomib-containing chemotherapy regimen.
  • Double-blind: A study design where neither the participants nor the researchers know who is receiving the actual treatment or a placebo.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs.
  • Open-label Extension (OLE): A phase of the study where all participants receive the actual drug being tested.
  • 6-Minute Walk Test (6MWT): A test that measures the distance an individual can walk in 6 minutes, used to assess physical function.
  • Short Form-36 (SF-36): A questionnaire used to measure health-related quality of life across various dimensions.
  • Bortezomib: A type of chemotherapy drug commonly used in the treatment of AL Amyloidosis.
  • Intravenous: Administration of a substance directly into a vein.